NCT04221945 2026-02-20KEYNOTE-A18Merck Sharp & Dohme LLCPhase 3 Completed1,060 enrolled 30 charts 1 FDA
NCT03635567 2026-02-04KEYNOTE-826Merck Sharp & Dohme LLCPhase 3 Completed617 enrolled 29 charts 1 FDA
NCT02628067 2025-09-22KEYNOTE 158Merck Sharp & Dohme LLCPhase 2 Active not recruiting1,609 enrolled 5 FDA
NCT03438396 2023-07-25A Trial of Tisotumab Vedotin in Cervical CancerSeagen Inc.Phase 2 Completed102 enrolled 20 charts 1 FDA
NCT01631552 2021-08-12Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerGilead SciencesPhase 1/2 Completed515 enrolled 28 charts 2 FDA